Vertex Inc. (VERX)
Vertex: Buy At Ultracheap Multiples, Product Is Safe From AI
Vertex has lost ~70% of its value despite steady growth and margin expansion, creating a compelling buy opportunity. VERX's FY26 guidance targets 10%-11% revenue growth and 23% adjusted EBITDA margin, trading at 2.9x EV/revenue and 12.5x EV/EBITDA. Fears of AI disruption are likely overstated given the complexity and risk of tax compliance, supporting Vertex's defensible niche.
Compared to Estimates, Vertex (VERX) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Vertex (VERX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex (VERX) Q4 Earnings Match Estimates
Vertex (VERX) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.15 per share a year ago.
Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards?
VRTX is set to report Q4 results amid strong Trikafta demand. Alyftrek launches are gaining traction while investors are eyeing Casgevy and Journavx sales.
Vertex Q4 Earnings Preview: What To Expect This Week
Vertex Pharmaceuticals is downgraded to Hold ahead of Q4 earnings due to underwhelming growth from key new drugs. Journavx and Casgevy sales remain niche, raising doubts about their ability to drive the next growth phase already priced into consensus. 2026 sales guidance and Q4 Journavx performance are critical; failure to beat expectations may trigger downside risk.
Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise
Vertex Pharmaceuticals remains a 'Top Idea' with robust Q3 earnings, a dominant CF franchise, and a broadening late-stage pipeline. VRTX's diversification into pain, kidney, cell, and gene therapies positions it for multiple launches between 2026–2028, supporting long-term growth. Financial strength is evident with $12B in cash, upgraded 2025 revenue guidance ($11.9B–$12B), and accelerating commercial momentum across new franchises.
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy"
Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities across its pipeline. JOURNAVX drives revenue with strong acute pain demand and is advancing into diabetic peripheral neuropathy (DPN) with two phase 3 studies enrolling through 2026. VRTX's BAFF/APRIL inhibitor povetacicept offers a 'pipeline in a pill' approach, targeting IgA Nephropathy and Primary Membranous Neuropathy, with key catalysts ahead and possible expansion opportunities.
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
After Plunging 17.7% in 4 Weeks, Here's Why the Trend Might Reverse for Vertex (VERX)
Vertex (VERX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Vertex Falls 10% After Reporting Mixed Q3 Results
Vertex (NASDAQ: VERX) delivered a split result this morning that left investors parsing mixed signals.
Vertex, Inc. (VERX) Q3 2025 Earnings Call Transcript
Vertex, Inc. ( VERX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Joseph Crivelli - Vice President of Investor Relations David DeStefano - CEO, President & Chairman of the Board John Schwab - Chief Financial Officer Conference Call Participants Joshua Reilly - Needham & Company, LLC, Research Division Christopher Quintero - Morgan Stanley, Research Division Alexander Sklar - Raymond James & Associates, Inc., Research Division Adam Hotchkiss - Goldman Sachs Group, Inc., Research Division Jacob Roberge - William Blair & Company L.L.C., Research Division Brett Huff - Stephens Inc., Research Division Steven Enders - Citigroup Inc., Research Division Andrew DeGasperi - BNP Paribas, Research Division Patrick Walravens - Citizens JMP Securities, LLC, Research Division Robert Oliver - Robert W.
